Clinical Trials · NCT04373967
Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrollment
- 424
- Start date
- Apr 2020
- Locations
- 46 sites, China
- Primary endpoint
- glycated hemoglobin (HbA1c)